Co-Authors
This is a "connection" page, showing publications co-authored by Shibo Jiang and Yuxian He.
Connection Strength
4.850
-
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006 Jun; 80(12):5757-67.
Score: 0.335
-
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006 May 15; 176(10):6085-92.
Score: 0.334
-
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006 Jun 29; 24(26):5498-508.
Score: 0.334
-
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem Biophys Res Commun. 2006 May 26; 344(1):106-13.
Score: 0.331
-
Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. 2005 Aug; 43(8):3718-26.
Score: 0.317
-
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005 Apr 15; 174(8):4908-15.
Score: 0.310
-
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology. 2005 Mar 30; 334(1):74-82.
Score: 0.309
-
Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol. 2005; 18(2):327-32.
Score: 0.304
-
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun. 2004 Dec 10; 325(2):445-52.
Score: 0.303
-
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004 Nov 12; 324(2):773-81.
Score: 0.301
-
Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol. 2004 Nov; 42(11):5309-14.
Score: 0.301
-
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol. 2004 Sep 15; 173(6):4050-7.
Score: 0.298
-
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010 Nov 04; 7:299.
Score: 0.114
-
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010 Apr; 23(2):211-9.
Score: 0.109
-
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009 Oct 10; 393(1):144-50.
Score: 0.105
-
Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009 Jul 10; 384(4):486-90.
Score: 0.103
-
Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. J Immunol. 2009 Apr 01; 182(7):4005-16.
Score: 0.102
-
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009 Mar; 7(3):226-36.
Score: 0.101
-
SARS vaccine development. Emerg Infect Dis. 2005 Jul; 11(7):1016-20.
Score: 0.079
-
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004 Mar 20; 363(9413):938-47.
Score: 0.072
-
Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020 09 25; 369(6511):1603-1607.
Score: 0.056
-
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020 07; 179:104820.
Score: 0.055
-
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008 Mar 20; 26(13):1644-51.
Score: 0.024
-
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol. 2008 Jan 15; 180(2):948-56.
Score: 0.023
-
Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc). 2008 Jan; 44(1):63-73.
Score: 0.023
-
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A. 2007 Jul 17; 104(29):12123-8.
Score: 0.023
-
Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007 Jul 20; 359(1):174-9.
Score: 0.022
-
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007 Apr 12; 25(15):2832-8.
Score: 0.022
-
Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology. 2006 Sep 15; 353(1):6-16.
Score: 0.021
-
rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine. 2005 May 16; 23(26):3446-52.
Score: 0.019